Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Leukemia

Acalabrutinib Shows Superior Efficacy Over Chemoimmunotherapy
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia. Read More ›

Maintaining an Intimate Relationship After a Cancer Diagnosis
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end. Read More ›

Tecartus, a CAR T-Cell Therapy, Leads to Complete Remissions in Patients with Acute Lymphoblastic Leukemia

FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection. Read More ›

A Look at Acalabrutinib Clinical Trials
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia. Read More ›

What Your Doctor Should Know About Your Quality of Life
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact. Read More ›

Lowering the Dose May Not Mean Less Effective Treatment
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features. Read More ›

Caregiving Strategies for Supporting Patients with CLL
By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them. Read More ›

Lessons Learned from My Journey with Chronic Lymphocytic Leukemia
George Valentine was diagnosed with chronic lymphocytic leukemia in 2002. He shares some of his hard-learned tips on how to deal with a cancer diagnosis and the high costs of treatment. Read More ›

Treatment of Chronic Lymphocytic Leukemia During the COVID-19 Pandemic
The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated. Read More ›

Page 3 of 13